Financial StabilityCash runway is expected to fund operations into the second half of 2027, providing financial stability for ongoing projects.
Market DifferentiationThe strategic shift towards leveraging their platform for siRNA therapeutics in autoimmune diseases is seen as a move in the right direction, focusing on differentiated technology.
Technological AdvancementRecent data demonstrated the effectiveness of ctLNPs in targeting T-cells, highlighting the potential of their technology in treating autoimmune diseases.